Effect of resistance to third-generation cephalosporins on morbidity and mortality from bloodstream infections in Blantyre, Malawi: a prospective cohort study.
Journal
The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
25
03
2022
revised:
13
09
2022
accepted:
13
09
2022
pubmed:
7
11
2022
medline:
7
12
2022
entrez:
6
11
2022
Statut:
ppublish
Résumé
The burden of antimicrobial resistance is a major threat to global health; however, prospective clinical outcome data from Africa are scarce. In Malawi, third-generation cephalosporins are the antibiotics of choice in patients admitted to hospital despite a rapid proliferation of resistance to these drugs. We aimed to quantify the effect of resistance to third-generation cephalosporins on mortality and length of hospital stay among patients with bloodstream infections. We did a prospective cohort study of patients admitted to Queen Elizabeth Central Hospital in Blantyre, Malawi. Patients of all ages who had positive blood cultures for Enterobacterales were included, with the exception of those from the genus Salmonella, and were followed up for 180 days. We characterised blood culture isolates using whole-genome sequencing and used Cox regression models to estimate the effect of resistance to third-generation cephalosporins on length of hospital stay, in-hospital mortality, and survival. Between Jan 31, 2018, and Jan 13, 2020, we recruited 326 patients, from whom 220 (68%) of 326 isolates were resistant to third-generation cephalosporins. The case fatality proportion was 45% (99 of 220) in patients with bloodstream infections that were resistant to third-generation cephalosporins, and 34% (36 of 106) in patients with bloodstream infections that were sensitive to third-generation cephalosporins. Resistance to third-generation cephalosporins was associated with an increased probability of in-hospital mortality (hazard ratio [HR] 1·44, 95% CI 1·02-2·04), longer hospital stays (1·5 days, 1·0-2·0) and decreased probability of discharge alive (HR 0·31, 0·22-0·45). Whole-genome sequencing showed a high diversity of sequence types of both Escherichia coli and Klebsiella pneumoniae. Although isolates associated with death were distributed across clades, we identified three E coli clades (ST410, ST617, and ST648) that were isolated from 14 patients who all died. Resistance to third-generation cephalosporins is associated with increased mortality and longer hospital stays in patients with bloodstream infections in Malawi. These data show the urgent need for allocation of resources towards antimicrobial resistance mitigation strategies in Africa. Wellcome Trust and Wellcome Asia and Africa Programme.
Sections du résumé
BACKGROUND
The burden of antimicrobial resistance is a major threat to global health; however, prospective clinical outcome data from Africa are scarce. In Malawi, third-generation cephalosporins are the antibiotics of choice in patients admitted to hospital despite a rapid proliferation of resistance to these drugs. We aimed to quantify the effect of resistance to third-generation cephalosporins on mortality and length of hospital stay among patients with bloodstream infections.
METHODS
We did a prospective cohort study of patients admitted to Queen Elizabeth Central Hospital in Blantyre, Malawi. Patients of all ages who had positive blood cultures for Enterobacterales were included, with the exception of those from the genus Salmonella, and were followed up for 180 days. We characterised blood culture isolates using whole-genome sequencing and used Cox regression models to estimate the effect of resistance to third-generation cephalosporins on length of hospital stay, in-hospital mortality, and survival.
FINDINGS
Between Jan 31, 2018, and Jan 13, 2020, we recruited 326 patients, from whom 220 (68%) of 326 isolates were resistant to third-generation cephalosporins. The case fatality proportion was 45% (99 of 220) in patients with bloodstream infections that were resistant to third-generation cephalosporins, and 34% (36 of 106) in patients with bloodstream infections that were sensitive to third-generation cephalosporins. Resistance to third-generation cephalosporins was associated with an increased probability of in-hospital mortality (hazard ratio [HR] 1·44, 95% CI 1·02-2·04), longer hospital stays (1·5 days, 1·0-2·0) and decreased probability of discharge alive (HR 0·31, 0·22-0·45). Whole-genome sequencing showed a high diversity of sequence types of both Escherichia coli and Klebsiella pneumoniae. Although isolates associated with death were distributed across clades, we identified three E coli clades (ST410, ST617, and ST648) that were isolated from 14 patients who all died.
INTERPRETATION
Resistance to third-generation cephalosporins is associated with increased mortality and longer hospital stays in patients with bloodstream infections in Malawi. These data show the urgent need for allocation of resources towards antimicrobial resistance mitigation strategies in Africa.
FUNDING
Wellcome Trust and Wellcome Asia and Africa Programme.
Identifiants
pubmed: 36335953
pii: S2666-5247(22)00282-8
doi: 10.1016/S2666-5247(22)00282-8
pmc: PMC9712123
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e922-e930Subventions
Organisme : Wellcome Trust
ID : 206545/Z/17/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests NAF received a Wellcome Asia and Africa Programme Grant to the Malawi Liverpool Wellcome Research Programme and a Medical Research Council programme grant. All other authors declare no competing interests.
Références
J Antimicrob Chemother. 2017 Jun 1;72(6):1602-1609
pubmed: 28333330
Front Microbiol. 2021 Dec 01;12:770130
pubmed: 34925277
Clin Infect Dis. 2022 May 30;74(10):1840-1849
pubmed: 34407175
Antimicrob Agents Chemother. 2010 May;54(5):2085-95
pubmed: 20176903
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Lancet Infect Dis. 2016 Jun;16(6):e92-e107
pubmed: 27049574
Sci Rep. 2022 Feb 3;12(1):1843
pubmed: 35115628
Commun Biol. 2019 Aug 29;2:322
pubmed: 31482141
Clin Infect Dis. 2020 Dec 3;71(9):e478-e486
pubmed: 32060523
Clin Infect Dis. 2009 Sep 1;49(5):682-90
pubmed: 19622043
Wellcome Open Res. 2020 Feb 13;5:29
pubmed: 32566760
World J Surg. 2016 Nov;40(11):2635-2642
pubmed: 27230398
Clin Microbiol Infect. 2016 May;22(5):416-22
pubmed: 26706614
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
PLoS Med. 2011 Oct;8(10):e1001104
pubmed: 22022233
Int J Infect Dis. 2015 Oct;39:1-6
pubmed: 26189774
AIDS. 2021 Nov 1;35(13):2191-2199
pubmed: 34172671
Wellcome Open Res. 2020 Jan 27;5:13
pubmed: 32509968
J Antimicrob Chemother. 2019 May 1;74(5):1223-1232
pubmed: 30778540
Trop Med Int Health. 2016 Aug;21(8):995-1002
pubmed: 27197651
Clin Microbiol Infect. 2021 Jun;27(6):846-853
pubmed: 33813126
J Antimicrob Chemother. 2012 Jun;67(6):1311-20
pubmed: 22396430
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
J Antimicrob Chemother. 2020 Mar 1;75(3):492-507
pubmed: 31742611